How effective are Apremilast tablets in treating psoriasis? Clinical research and patient feedback

Apremilast tablets, as an oral small molecule drug, have attracted much attention in the field of psoriasis (Psoriasis) treatment in recent years. Its unique mechanism of action and favorable safety profile make it an emerging treatment option for patients with moderate to severe psoriasis. This article will analyze in detail the performance of Apremilast in the treatment of psoriasis from four aspects: clinical research data, treatment effects, patient feedback and application suggestions.

First of all, the mechanism of action of Apremilast is mainly through selective inhibition of phosphodiesterase 4 (PDE4), thereby regulating intracellular cyclic adenosine monophosphate (cAMP) levels, thereby affecting the production of a variety of inflammatory mediators and reducing pro-inflammatory factors such as tumor necrosis factor α (cAMP secretion of interleukin -17 (IL-17) and interleukin -23 (IL-23). Psoriasis is a chronic inflammatory skin disease whose pathogenesis involves abnormal activation of the immune system, especially the overexpression of the above-mentioned inflammatory factors. By inhibiting these key inflammatory mediators, Apremilast can effectively reduce skin inflammation and scales and improve the skin condition of diseased areas.

In terms of clinical research, the efficacy of Apremilast has been confirmed through multiple large randomized controlled trials. ESTEEM 1 and ESTEEM 2Two pivotal studies included more than 1,200 patients with moderate to severe psoriasis. Study results show that after taking Apremilast for 12 weeks, approximately 33% to 40% of patients achieved PASI. 75 (the psoriasis area and severity index was reduced by 75%), significantly better than the placebo group. With longer treatment, especially 52 weeks of continuous use, the patient's symptoms were further relieved and the efficacy was stable. In addition, Apremilast also has a positive effect on joint symptoms, helping patients with psoriatic arthritis relieve joint pain and swelling and improve joint function.

Judging from patient feedback, the convenience of oral administration of Apremilast is generally recognized. Compared with biological agents that require injection, Apremilast avoids injection pain and related operational risks, improving patient compliance. Most patients report that their symptoms of skin itching, erythema, and scaling have improved after taking the medicine for a few weeks, and their quality of life has improved. Common adverse reactions include mild gastrointestinal upset, such as diarrhea, nausea, and headache, which in most cases are mild and transient. Patients can adjust their medication under the guidance of a physician, and side effects can usually be effectively controlled without affecting long-term treatment.

Taken together, Apremilast provides an effective and convenient treatment option for patients with moderate to severe psoriasis due to its unique immunomodulatory effect and low risk of side effects. Although its efficacy is not as strong as that of some biological agents in some patients, the advantages and good safety profile of oral administration make it of great clinical value. During the treatment with Apremilast, patients should strictly follow the doctor's instructions, follow up regularly, and give timely feedback on medication effects and adverse reactions so that doctors can make reasonable treatment adjustments to achieve the best treatment effect and improvement in quality of life.

Reference materials:https://go.drugbank.com/drugs/DB05676